University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Rahul Aggarwal, MD

Rahul Aggarwal, MD

Assistant Professor of Hematology/Oncology, Director of STAND Clinic, UCSF

Cancer Center Program Memberships

Prostate Cancer | Experimental Therapeutics

Research Summary

I am an Assistant Clinical Professor of Medicine in the Department of Medicine, Division of Hematology/Oncology at UCSF within the Genitourinary Oncology and Developmental Therapuetics programs. My research program is focused upon developing novel therapeutic and imaging strategies for patients with advanced prostate cancer. I serve as Co-Investigator in the ongoing Prostate Cancer Foundation/SU2C-funded West Coast Dream Team prostate cancer consortium, focused on clinically and genomically characterizing metastatic tumor biopsies, including those with oligometastatic disease. Thus far approximately 10% of our patients have oligometastatic disease, and we anticipate a larger percentage as begin to biopsy patients earlier in their disease course. The infrastructure of this program will provide the mechanism to genomically characterize oligometastatic disease and compare with patients with more extensive disease, to understand if there are intrinsic biologic differences between these disease subtypes.

Education

Northwestern University, Evanston, IL, BA, 1999-2002, Psychology
Northwestern University Feinberg School of Medicine, Chicago, IL, MD, 2002-2006, Medicine


Professional Experience

  • 2006 – 2009
    Internal Medicine Internship and Residency Training Program, UCSF
  • 2009 – 2010
    Clinical Oncology Fellowship, Genentech, Inc. South San Francisco, CA
  • 2010 – 2013
    Clinical Fellow, Division of Hematology/Oncology, UCSF
  • 2013 - present
    Assistant Professor of Clinical Medicine, Genitourinary Medical Oncology UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 2001
    James Alton James Scholarship, Northwestern University
  • 2002
    James A. Patten Scholarship, Northwestern University
  • 2002
    Phi Beta Kappa Centennial Award, Northwestern University
  • 2002
    Summa Cum Laude, Northwestern University
  • 2004
    Department of Medicine Chairman’s Award, Northwestern University School of Medicine
  • 2005
    Member Alpha Omega Alpha medical honor society
  • 2011
    Pfizer Fellowships in Oncology Award in collaboration with UCSF Division of Hematology/Oncology, Department of Medicine
  • 2012
    Young Investigator Award, American Society of Clinical Oncology/Conquer Cancer Foundation
  • 2012
    Inaugural Recipient, Ronald A. Rosenberg Fellowship in Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2013
    Alliance Cooperative Group Scholar Award
  • 2014
    The Sence Foundation Award
  • 2015
    Prostate Cancer Foundation Young Investigator Award
  • 2016
    Department of Defense Prostate Cancer Research Program Physician Research Training Award

Selected Publications

  1. Aggarwal R, Behr S, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Premasekharan G, Huang J, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. Real time transferrin-based PET detects MYC-positive prostate cancer. Mol Cancer Res. 2017 Jun 07.
    View on PubMed
  2. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Jun 03.
    View on PubMed
  3. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg M, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 May 18.
    View on PubMed
  4. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard CC, Thomas GV, Tomlins SA, Knudsen KE, Lord CJ, Ryan CJ, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 Apr 27.
    View on PubMed
  5. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Feb 21; JCO2016705350.
    View on PubMed
  6. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Feb 01.
    View on PubMed
  7. Hope TA, Truillet CC, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience. J Nucl Med. 2016 Sep 22.
    View on PubMed
  8. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncol. 2016 Jul 25.
    View on PubMed
  9. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. A Feasibility Study Showing [(68)Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 May 16.
    View on PubMed
  10. Aggarwal R. Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure? Eur Urol. 2016 Sep; 70(3):445-6.
    View on PubMed
  11. Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R. Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 Aug; 34(8):368-74.
    View on PubMed
  12. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 May; 27(5):947-52.
    View on PubMed
  13. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9.
    View on PubMed
  14. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1.
    View on PubMed
  15. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8.
    View on PubMed
  16. Aggarwal RR, Small EJ. Small-cell/neuroendocrine prostate cancer: a growing threat? Oncology (Williston Park). 2014 Oct; 28(10):838-40.
    View on PubMed
  17. Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014 Aug; 74(2):359-65.
    View on PubMed
  18. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014 May; 12(5):719-26.
    View on PubMed
  19. Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014 Oct; 12(5):e167-72.
    View on PubMed
  20. Aggarwal R, Kurhanewicz J. The changing role of imaging in clinical care. Nat Rev Urol. 2014 Feb; 11(2):75-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI